Literature DB >> 115901

Purinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts.

J M Wilson, B S Mitchell, P E Daddona, W N Kelley.   

Abstract

Deoxyadenosine and deoxyguanosine are toxic to human lymphoid cells in culture and have been implicated in the pathogenesis of the immunodeficiency states associated with adenosine deaminase and purine nucleoside phosphorylase deficiency, respectively. We have studied the relative incorporation of several labeled nucleosides into DNA and into nucleotide pools to further elucidate the mechanism of deoxyribonucleoside toxicity. In the presence of an inhibitor of adenosine deaminase [erythro-9-(2-hydroxy-3-nonyl)adenine [EHNA], 5 muM], deoxyadenosine (1-50 muM) progressively decreased the incorporation of thymidine, uridine, and deoxyuridine into DNA, but did not affect uridine incorporation into RNA. This decrease in DNA synthesis was associated with increasing dATP and decreasing dCTP pools. Likewise, incubation of cells with deoxyguanosine caused an elevation of dGTP, depletion of dCTP, and inhibition of DNA synthesis. To test the hypothesis that dATP and dGTP accumulation inhibit DNA synthesis by inhibiting the enzyme ribonucleotide reductase, simultaneous rates of incorporation of [(3)H]uridine and [(14)C]thymidine into DNA were measured in the presence of deoxyadenosine plus EHNA or deoxyguanosine, and in the presence of hydroxyurea, a known inhibitor of ribonucleotide reductase. Hydroxyurea (100 muM) and deoxyguanosine (10 muM) decreased the incorporation of [(3)H]uridine but not of [(14)C]thymidine into DNA; both compounds also substantially increased [(3)H]cytidine incorporation into the ribonucleotide pool while reducing incorporation into the deoxyribonucleotide pool. In contrast, deoxyadenosine plus EHNA did not show this differential inhibition of [(3)H]uridine incorporation into DNA, and the alteration in [(3)H]cytidine incorporation into nucleotide pools was less impressive. These data show an association between accumulation of dATP or dGTP and a primary inhibition of DNA synthesis, and they provide support for ribonucleotide reductase inhibition as the mechanism responsible for deoxyguanosine toxicity. Deoxyadenosine toxicity, however, appears to result from another, or perhaps a combination of, molecular event(s).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 115901      PMCID: PMC371297          DOI: 10.1172/JCI109606

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease.

Authors:  B Ullman; L J Gudas; S M Clift; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

2.  A patient with nucleoside phosphorylase deficiency, selective t-cell deficiency, and autoimmune hemolytic anemia.

Authors:  E Carapella-de Luca; F Aiuti; P Lucarelli; L Bruni; C D Baroni; C Imperato; D Roos; A Astaldi
Journal:  J Pediatr       Date:  1978-12       Impact factor: 4.406

3.  A NEW METHOD FOR THE DETERMINATION OF THE BASE COMPOSITION OF RIBONUCLEIC ACID.

Authors:  S KATZ; D G COMB
Journal:  J Biol Chem       Date:  1963-09       Impact factor: 5.157

4.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

5.  Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease.

Authors:  B Ullman; L J Gudas; A Cohen; D W Martin
Journal:  Cell       Date:  1978-06       Impact factor: 41.582

6.  Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine.

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

7.  Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease.

Authors:  J Donofrio; M S Coleman; J J Hutton; A Daoud; B Lampkin; J Dyminski
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

8.  Deoxyadenosine metabolism and toxicity in cultured L5178Y cells.

Authors:  J K Lowe; B Gowans; L Brox
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

9.  Cellular immune deficiency with autoimmune hemolytic anemia in purine nucleoside phosphorylase deficiency.

Authors:  K C Rich; W J Arnold; T Palella; I H Fox
Journal:  Am J Med       Date:  1979-07       Impact factor: 4.965

10.  Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.

Authors:  A Cohen; R Hirschhorn; S D Horowitz; A Rubinstein; S H Polmar; R Hong; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

View more
  12 in total

1.  Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.

Authors:  D S Duan; T Nagashima; T Hoshino; F Waldman; K Pawlak; W Sadee
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

2.  Adenosine deaminase polymorphism. Associations at clinical level suggest a role in cell functions and immune reactions.

Authors:  E Bottini; E Carapella; L Cataldi; M Nicotra; P Lucarelli; N Lucarini; R Pascone; F Gloria-Bottini
Journal:  J Med Genet       Date:  1981-10       Impact factor: 6.318

3.  The metabolism of deoxyguanosine and guanosine in human B and T lymphoblasts. A role for deoxyguanosine kinase activity in the selective T-cell defect associated with purine nucleoside phosphorylase deficiency.

Authors:  W R Osborne; C R Scott
Journal:  Biochem J       Date:  1983-09-15       Impact factor: 3.857

4.  Deoxycoformycin: neurological toxicity.

Authors:  P P Major; R P Agarwal; D W Kufe
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  "Reverse" carbocyclic fleximers: synthesis of a new class of adenosine deaminase inhibitors.

Authors:  Sarah C Zimmermann; Joshua M Sadler; Peter I O'Daniel; Nathaniel T Kim; Katherine L Seley-Radtke
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2013       Impact factor: 1.381

6.  Interaction between ABO blood groups and ADA genetic polymorphism during intrauterine life. A comparative analysis of couples with habitual abortion and normal puerperae delivering a live-born infant.

Authors:  N Lucarini; M Nicotra; F Gloria-Bottini; P Borgiani; A Amante; C Muttinelli; F Signoretti; M La Torre; E Bottini
Journal:  Hum Genet       Date:  1995-11       Impact factor: 4.132

7.  ATP depletion as a consequence of adenosine deaminase inhibition in man.

Authors:  M F Siaw; B S Mitchell; C A Koller; M S Coleman; J J Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

8.  Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblasts.

Authors:  G J Mann; R M Fox
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

9.  2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation.

Authors:  Y Sidi; B S Mitchell
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

10.  The effect of G2-treatments with 2'-deoxyadenosine on the frequency of chromatid aberrations in human lymphocytes depends on the type of culture.

Authors:  B A Kihlman; H C Andersson
Journal:  Chromosoma       Date:  1984       Impact factor: 4.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.